{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:06:47Z","timestamp":1779916007975,"version":"3.53.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Inflammatory bowel disease (IBD) is chronic inflammation of the gastrointestinal tract, although its etiology has largely been unclear. Tumor necrosis factor inhibitors (TNF-I) are effective for the treatment. Recently, biosimilars of TNF-I, such as CT-P13, have been developed and are thought to possess equal efficacy and safety to the original TNF-I. Sarcoidosis is also a systemic granulomatous disease of unknown etiology. In steroid-resistant cases of sarcoidosis, TNF-I have been reported effective for achieving resolution. However, the progression of sarcoidosis due to the TNF-I also has been reported. We herein report a case of pulmonary sarcoidosis with a Crohn\u2019s disease (CD) patient developed after a long period administration (15 years) of TNF-I.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentations<\/jats:title><jats:p>A 37-year-old woman with CD who had been diagnosed at 22\u00a0years old had been treated with the TNF-I (original infliximab; O-IFX and infliximab biosimilar; IFX-BS). Fifteen years after starting the TNF-I, she developed a fever and right chest pain. Chest computed tomography (CT) revealed clustered small nodules in both lungs and multiple enlarged hilar lymph nodes. Infectious diseases including tuberculosis were negative. Bronchoscopic examination was performed and the biopsy specimens were obtained. A pathological examination demonstrated noncaseating granulomatous lesions and no malignant findings. TNF-I were discontinued because of the possibility of TNF-I-related sarcoidosis. After having discontinued for four months, her symptoms and the lesions had disappeared completely. Fortunately, despite the discontinuation of TNF-I, she has maintained remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>To our knowledge, this is the first case in which sarcoidosis developed after switching from O-IFX to IFX-BS. To clarify the characteristics of the cases with development of sarcoidosis during administration of TNF-I, we searched PubMed and identified 106 cases. When developing an unexplained fever, asthenia, uveitis and skin lesions in patients with TNF-I treatment, sarcoidosis should be suspected. Once the diagnosis of sarcoidosis due to TNF-I was made, the discontinuation of TNF-I and administration of steroid therapy should be executed promptly. When re-starting TNF-I, another TNF-I should be used for disease control. Clinicians should be aware of the possibility of sarcoidosis in patients under anti-TNF therapy.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12876-021-01948-6","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T01:07:06Z","timestamp":1634087226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Development of pulmonary sarcoidosis in Crohn\u2019s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8309-4281","authenticated-orcid":false,"given":"Shin","family":"Kashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Moriichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Yuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikihiro","family":"Fujiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"1948_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","volume":"63","author":"ME van der Valk","year":"2014","unstructured":"van der Valk ME, Mangen MJJ, Leenders M, et al. Health care costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study. Gut. 2014;63:72\u20139.","journal-title":"Gut"},{"key":"1948_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apt.14997","volume":"49","author":"BG Feagan","year":"2019","unstructured":"Feagan BG, Lam G, Ma C, et al. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2019;49:31\u201340.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10182","key":"1948_CR3","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","volume":"393","author":"BD Ye","year":"2019","unstructured":"Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\u2019s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393(10182):1699\u2013707.","journal-title":"Lancet"},{"key":"1948_CR4","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1053\/j.gastro.2014.12.040","volume":"148","author":"DA Simonetto","year":"2015","unstructured":"Simonetto DA, Papadakis KA. New-onset paresthesias in inflammatory bowel disease. Gastroenterology. 2015;148:906\u20137.","journal-title":"Gastroenterology"},{"key":"1948_CR5","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.crohns.2014.02.006","volume":"8","author":"MJ McDonnell","year":"2014","unstructured":"McDonnell MJ, Rutherford RM, O\u2019Regan A. Sarcoidosis complicating treatment with adalimumab for Crohn\u2019s disease. J Crohns Colitis. 2014;8:1140\u20131.","journal-title":"J Crohns Colitis"},{"key":"1948_CR6","doi-asserted-by":"publisher","first-page":"e599","DOI":"10.1016\/j.crohns.2013.06.002","volume":"7","author":"PG Kotze","year":"2013","unstructured":"Kotze PG, de Barcelos IF, da Silva Kotze LM. Sarcoidosis during therapy with adalimumab in a Crohn\u2019s disease patient: a paradoxical effect. J Crohns Colitis. 2013;7:e599-600.","journal-title":"J Crohns Colitis"},{"key":"1948_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1346-8138.2010.00861.x","volume":"37","author":"H Takahashi","year":"2010","unstructured":"Takahashi H, Kaneta K, Honma M, et al. Sarcoidosis during infliximab therapy for Crohn\u2019s disease. J Dermatol. 2010;37:471\u20134.","journal-title":"J Dermatol"},{"key":"1948_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3393\/ac.2017.33.2.74","volume":"33","author":"KK Tae","year":"2017","unstructured":"Tae KK, Sun HK, Hee SM, et al. Pulmonary sarcoidosis that developed during the treatment of a patient with Crohn disease by using infliximab. Ann Coloproctol. 2017;33:74\u20137.","journal-title":"Ann Coloproctol"},{"key":"1948_CR9","first-page":"378","volume":"11","author":"A Decock","year":"2017","unstructured":"Decock A, Van Assche G, Vermeire S, et al. Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy? J Crohns Colitis. 2017;11:378\u201383.","journal-title":"J Crohns Colitis"},{"key":"1948_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1159\/000275676","volume":"220","author":"F Dhaille","year":"2010","unstructured":"Dhaille F, Viseux V, Caudron A, et al. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology. 2010;220:234\u20137.","journal-title":"Dermatology"},{"key":"1948_CR11","doi-asserted-by":"crossref","unstructured":"Van Der Stoep D, Braunstahl G, Van Zeben J, Wouters J. Sarcoidosis during anti-tumor necrosis factor-\u03b1 therapy: no relapse after rechallenge in rheumatology and related fields. J Rheumatol. 2009; 36.","DOI":"10.3899\/jrheum.090307"},{"key":"1948_CR12","first-page":"471","volume":"26","author":"\u00c9 Toussirot","year":"2008","unstructured":"Toussirot \u00c9, Pertuiset \u00c9, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-\u03b1 treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol. 2008;26:471\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"1948_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/rheumatology\/kep046","volume":"48","author":"CI Da\u00efen","year":"2009","unstructured":"Da\u00efen CI, Monnier A, Claudepierre P, Constantin A, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48:883\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"1948_CR14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.semarthrit.2008.11.003","volume":"39","author":"A Massara","year":"2010","unstructured":"Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumoical phenomenon. Two case reports and literature review. Semin Arthritis Rheum. 2010;39:313\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"1948_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.lpm.2014.06.028","volume":"44","author":"L-M Scailteux","year":"2015","unstructured":"Scailteux L-M, Guedes C, Polard E, Perdriger A. Sarcoidosis after adalimumab treatment in inflammatory rheumatic diseases: a report of two cases and literature review. Presse Med. 2015;44:4\u201310.","journal-title":"Presse Med"},{"key":"1948_CR16","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/1756-185X.12178","volume":"17","author":"R Miyagi","year":"2014","unstructured":"Miyagi R, Ideguchi H, Soga T, et al. Development of pulmonary and cardiac sarcoidosis during etanercept therapy. Int J Rheum Dis. 2014;17:810\u20132.","journal-title":"Int J Rheum Dis"},{"key":"1948_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.rmr.2013.04.029","volume":"31","author":"A Watrin","year":"2014","unstructured":"Watrin A, Royer M, Legrand E, et al. Severe hypercalcemia revealing sarcoidosis precipitated by etanercept. Rev Mal Respir. 2014;31:255\u20138.","journal-title":"Rev Mal Respir"},{"key":"1948_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/1471-2377-13-212","volume":"13","author":"C-A Durel","year":"2013","unstructured":"Durel C-A, Feurer E, Pialat J-B, et al. Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis. BMC Neurol. 2013;13:212.","journal-title":"BMC Neurol"},{"key":"1948_CR19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/1756-185X.12078","volume":"16","author":"M Alhajri","year":"2013","unstructured":"Alhajri M, Aljumaah S, Aleyouni Y, et al. Granulomatous disease in a child treated with etanercept. Int J Rheum Dis. 2013;16:472\u20134.","journal-title":"Int J Rheum Dis"},{"key":"1948_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.amjoto.2012.12.016","volume":"34","author":"A Christoforidou","year":"2013","unstructured":"Christoforidou A, Goudakos J, Bobos M, et al. Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy. Am J Otolaryngol. 2013;34:268\u201372.","journal-title":"Am J Otolaryngol"},{"issue":"6 Suppl 1","key":"1948_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1590\/abd1806-4841.20132588","volume":"88","author":"N Unterstell","year":"2013","unstructured":"Unterstell N, Bressan AL, Serpa LA, et al. Systemic sarcoidosis induced by etanercept: first Brazilian case report. An Bras Dermatol. 2013;88(6 Suppl 1):197\u20139.","journal-title":"An Bras Dermatol"},{"key":"1948_CR22","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1111\/j.1440-0960.2011.00863.x","volume":"53","author":"E Lamrock","year":"2012","unstructured":"Lamrock E, Brown P. Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists. Australas J Dermatol. 2012;53:e87-90.","journal-title":"Australas J Dermatol"},{"key":"1948_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1445-5994.2011.02612.x","volume":"42","author":"D Tong","year":"2012","unstructured":"Tong D, Manolios N, Howe G, et al. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Intern Med J. 2012;42:89\u201394.","journal-title":"Intern Med J"},{"key":"1948_CR24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.crohns.2012.01.008","volume":"6","author":"KC Fok","year":"2012","unstructured":"Fok KC, Ng WWS, Henderson CJ, et al. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J Crohns Colitis. 2012;6:708\u201312.","journal-title":"J Crohns Colitis"},{"key":"1948_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/09273948.2011.623213","volume":"20","author":"P Seve","year":"2012","unstructured":"Seve P, Varron L, Broussolle C, et al. Sarcoid-related uveitis occurring during adalimumab therapy. Ocul Immunol Inflamm. 2012;20:59\u201360.","journal-title":"Ocul Immunol Inflamm"},{"key":"1948_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3109\/09273948.2011.623212","volume":"20","author":"A Fonollosa","year":"2012","unstructured":"Fonollosa A, Artaraz J, Les I, et al. Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature. Ocul Immunol Inflamm. 2012;20:44\u20138.","journal-title":"Ocul Immunol Inflamm"},{"key":"1948_CR27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00296-009-1349-x","volume":"32","author":"IM Skoie","year":"2012","unstructured":"Skoie IM, Wildhagen K, Omdal R. Development of sarcoidosis following etanercept treatment: a report of three cases. Rheumatol Int. 2012;32:1049\u201353.","journal-title":"Rheumatol Int"},{"key":"1948_CR28","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s10067-011-1704-7","volume":"30","author":"M Haroon","year":"2011","unstructured":"Haroon M, Ryan JG, Harney S. Development of sarcoidosis 6-month post discontinuation of etanercept: coincidence or real association? Clin Rheumatol. 2011;30:1095\u20138.","journal-title":"Clin Rheumatol"},{"key":"1948_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.arbres.2010.05.011","volume":"47","author":"L Gifre","year":"2011","unstructured":"Gifre L, Ruiz-Esquide V, Xaubet A, et al. Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. Arch Bronconeumol. 2011;47:208\u201312.","journal-title":"Arch Bronconeumol"},{"key":"1948_CR30","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/rheumatology\/ker166","volume":"50","author":"J Salvatierra","year":"2011","unstructured":"Salvatierra J, Magro-Checa C, Rosales-Alexander JL, et al. Acute sarcoidosis as parotid fever in rheumatoid arthritis under anti-tumor necrosis factor-alpha therapy. Rheumatology (Oxford). 2011;50:1346\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"1948_CR31","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.rmr.2010.08.018","volume":"28","author":"M Kerjouan","year":"2011","unstructured":"Kerjouan M, Jouneau S, Lena H, et al. Pulmonary sarcoidosis developing during treatment with etanercept. Rev Mal Respir. 2011;28:360\u20134.","journal-title":"Rev Mal Respir"},{"key":"1948_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10067-010-1603-3","volume":"30","author":"T Kanellopoulou","year":"2011","unstructured":"Kanellopoulou T, Filiotou A, Kranidioti H, et al. Sarcoid-like granulomatosis in patients treated with anti-TNF\u03b1 factors. A case report and review of the literature. Clin Rheumatol. 2011;30:581\u20133.","journal-title":"Clin Rheumatol"},{"key":"1948_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10067-010-1577-1","volume":"30","author":"R Cuchacovich","year":"2011","unstructured":"Cuchacovich R, Hagan J, Khan T, et al. Tumor necrosis factor-alpha (TNF-\u03b1)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature. Clin Rheumatol. 2011;30:133\u20137.","journal-title":"Clin Rheumatol"},{"key":"1948_CR34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/RHU.0b013e3181efa190","volume":"16","author":"RR Clementine","year":"2010","unstructured":"Clementine RR, Lyman J, Zakem J, et al. Tumor necrosis factor-alpha antagonist-induced sarcoidosis. J Clin Rheumatol. 2010;16:274\u20139.","journal-title":"J Clin Rheumatol"},{"key":"1948_CR35","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1365-2133.2010.09843.x","volume":"163","author":"AE Pink","year":"2010","unstructured":"Pink AE, Fonia A, Smith CH, et al. The development of sarcoidosis on antitumour necrosis factor therapy: a paradox. Br J Dermatol. 2010;163:648\u20139.","journal-title":"Br J Dermatol"},{"key":"1948_CR36","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1111\/j.1440-0960.2010.00660.x","volume":"52","author":"S Marcella","year":"2011","unstructured":"Marcella S, Welsh B, Foley P. Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis. Australas J Dermatol. 2011;52:e8-11.","journal-title":"Australas J Dermatol"},{"key":"1948_CR37","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3899\/jrheum.090647","volume":"37","author":"S Takatori","year":"2010","unstructured":"Takatori S, Kamata Y, Murosaki T, et al. Abrupt development of sarcoidosis with a prodromal increase in plasma osteopontin in a patient with rheumatoid arthritis during treatment with etanercept. J Rheumatol. 2010;37:210\u20131.","journal-title":"J Rheumatol"},{"key":"1948_CR38","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/j.1365-4632.2009.04080.x","volume":"48","author":"M Samimi","year":"2009","unstructured":"Samimi M, Lorette G, Machet L, et al. Facial granulomatous nodules during etanercept treatment for psoriasis. Int J Dermatol. 2009;48:1025\u20137.","journal-title":"Int J Dermatol"},{"key":"1948_CR39","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.3899\/jrheum.090030","volume":"36","author":"E Toussirot","year":"2009","unstructured":"Toussirot E, Berthelot JM, Pertuiset E, et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. J Rheumatol. 2009;36:2421\u20137.","journal-title":"J Rheumatol"},{"key":"1948_CR40","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10384-009-0691-6","volume":"53","author":"J Suzuki","year":"2009","unstructured":"Suzuki J, Goto H. Uveitis associated with sarcoidosis exacerbated by etanercept therapy. Jpn J Ophthalmol. 2009;53:439\u201340.","journal-title":"Jpn J Ophthalmol"},{"key":"1948_CR41","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jbspin.2009.02.003","volume":"76","author":"S Josse","year":"2009","unstructured":"Josse S, Klemmer N, Moreno-Swirc S, et al. Infliximab induced skin and pulmonary sarcoidosis in a rheumatoid arthritis patient. Joint Bone Spine. 2009;76:718\u20139.","journal-title":"Joint Bone Spine"},{"key":"1948_CR42","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2169\/internalmedicine.47.0602","volume":"47","author":"T Ishiguro","year":"2008","unstructured":"Ishiguro T, Takayanagi N, Kurashima K, et al. Development of sarcoidosis during etanercept therapy. Intern Med. 2008;47:1021\u20135.","journal-title":"Intern Med"},{"key":"1948_CR43","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2007.078840","volume":"67","author":"GH Louie","year":"2008","unstructured":"Louie GH, Chitkara P, Ward MM. Relapse of sarcoidosis upon treatment with etanercept. Ann Rheum Dis. 2008;67:896\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1948_CR44","first-page":"349","volume":"35","author":"M Farah","year":"2008","unstructured":"Farah M, Al Rashidi A, Owen DA, et al. Granulomatous hepatitis associated with etanercept therapy. J Rheumatol. 2008;35:349\u201351.","journal-title":"J Rheumatol"},{"key":"1948_CR45","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1592\/phco.27.10.1446","volume":"27","author":"RE Farah","year":"2007","unstructured":"Farah RE, Shay MD. Pulmonary sarcoidosis associated with etanercept therapy. Pharmacotherapy. 2007;27:1446\u20138.","journal-title":"Pharmacotherapy"},{"key":"1948_CR46","first-page":"12","volume":"34","author":"G Sturfelt","year":"2007","unstructured":"Sturfelt G, Christensson B, Bynke G, et al. Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields. J Rheumatol. 2007;34:12\u20136.","journal-title":"J Rheumatol"},{"key":"1948_CR47","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s10067-007-0594-1","volume":"26","author":"K Verschueren","year":"2007","unstructured":"Verschueren K, Van Essche E, Verschueren P, et al. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol. 2007;26:1969\u201371.","journal-title":"Clin Rheumatol"},{"key":"1948_CR48","first-page":"99","volume":"25","author":"R Almod\u00f3var","year":"2007","unstructured":"Almod\u00f3var R, Izquierdo M, Zarco P, et al. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol. 2007;25:99\u2013101.","journal-title":"Clin Exp Rheumatol"},{"key":"1948_CR49","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-3083.2006.01949.x","volume":"21","author":"C Bachmeyer","year":"2007","unstructured":"Bachmeyer C, Blum L, Petitjean B, et al. Granulomatous tattoo reaction in a patient treated with etanercept. J Eur Acad Dermatol Venereol. 2007;21:550\u20132.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1948_CR50","first-page":"648","volume":"34","author":"A Kudrin","year":"2007","unstructured":"Kudrin A, Chilvers ER, Ginawi A, et al. Sarcoid-like granulomatous disease following etanercept treatment for RA. J Rheumatol. 2007;34:648\u20139.","journal-title":"J Rheumatol"},{"key":"1948_CR51","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/art.22238","volume":"55","author":"MA Gonz\u00e1lez-L\u00f3pez","year":"2006","unstructured":"Gonz\u00e1lez-L\u00f3pez MA, Blanco R, Gonz\u00e1lez-Vela MC, et al. Development of sarcoidosis during etanercept therapy. Arthritis Rheum. 2006;55:817\u201320.","journal-title":"Arthritis Rheum"},{"key":"1948_CR52","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/art.22351","volume":"55","author":"FD O\u2019Shea","year":"2006","unstructured":"O\u2019Shea FD, Marras TK, Inman RD. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum. 2006;55:978\u201381.","journal-title":"Arthritis Rheum"},{"key":"1948_CR53","first-page":"645","volume":"21","author":"PJ Hashkes","year":"2003","unstructured":"Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol. 2003;21:645\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"1948_CR54","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1002\/art.11154","volume":"48","author":"O H\u00fcbscher","year":"2003","unstructured":"H\u00fcbscher O, Re R, Iotti R. Pulmonary rheumatoid nodules in an etanercept-treated patient. Arthritis Rheum. 2003;48:2077\u20138.","journal-title":"Arthritis Rheum"},{"key":"1948_CR55","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1378\/chest.122.5.1858","volume":"122","author":"L Peno-Green","year":"2002","unstructured":"Peno-Green L, Lluberas G, Kingsley T, et al. Lung injury linked to etanercept therapy. Chest. 2002;122:1858\u201360.","journal-title":"Chest"},{"key":"1948_CR56","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/ki.2013.452","volume":"86","author":"V Morgane","year":"2014","unstructured":"Morgane V, Jean-Charles C, Nicolas M, et al. Renal sarcoid-like granulomatosis during anti-TNF therapy. Kidney Int. 2014;86:215.","journal-title":"Kidney Int"},{"key":"1948_CR57","doi-asserted-by":"crossref","unstructured":"Dorta ZK, Ochieng P, Donald F, et al. Pulmonary sarcoidosis and latent tuberculosis in a patient with psoriasis treated with adalimumab. Dermatol Online J. 2015.","DOI":"10.5070\/D3211025451"},{"key":"1948_CR58","first-page":"7121539","volume":"8","author":"BN Nnodum","year":"2019","unstructured":"Nnodum BN, Hariri LP, Mavrommati D, Dudley L, et al. A case of severe symptomatic central nervous system sarcoidosis secondary to treatment with adalimumab. Case Rep Rheumatol. 2019;8:7121539.","journal-title":"Case Rep Rheumatol."},{"key":"1948_CR59","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/ajh.25021","volume":"93","author":"V Leventaki","year":"2018","unstructured":"Leventaki V, Flerlage J. Sarcoid-like granulomatosis in a patient receiving anti-TNF\u03b1 for psoriasis. Am J Hematol. 2018;93:722\u20133.","journal-title":"Am J Hematol"},{"key":"1948_CR60","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3349\/ymj.2016.57.1.272","volume":"57","author":"JK Sim","year":"2016","unstructured":"Sim JK, Lee SY, Shim JJ, Kang KH, et al. Pulmonary sarcoidosis induced by adalimumab: a case report and literature review. Yonsei Med J. 2016;57:272\u20133.","journal-title":"Yonsei Med J"},{"key":"1948_CR61","doi-asserted-by":"publisher","first-page":"6156","DOI":"10.1097\/MD.0000000000006156","volume":"96","author":"GE G\u00eelc\u0103","year":"2017","unstructured":"G\u00eelc\u0103 GE, Diaconescu S, B\u0103lan GG, Timofte O, \u015etef\u0103nescu G, et al. Sarcoidosis associated with infliximab therapy in ulcerative colitis: a case report. Medicine (Baltimore). 2017;96:6156.","journal-title":"Medicine (Baltimore)"},{"key":"1948_CR62","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1097\/IOP.0000000000000200","volume":"32","author":"EJ Wladis","year":"2016","unstructured":"Wladis EJ, Tarasen AJ, Roth ZJ, et al. Orbital sarcoid-like granulomatosis after inhibition of tumor necrosis factor-\u03b1. Ophthalmic Plast Reconstr Surg. 2016;32:e30\u20132.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"1948_CR63","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/DAD.0000000000001394","volume":"41","author":"Y Turkowski","year":"2019","unstructured":"Turkowski Y, Konnikov N, Mahalingam M. Necrotizing granulomas in a patient with psoriasis and sarcoidosis after adalimumab-medication-induced reaction or reactivation of latent disease? Am J Dermatopathol. 2019;41:661\u20136.","journal-title":"Am J Dermatopathol"},{"key":"1948_CR64","doi-asserted-by":"publisher","first-page":"bcr2013200552","DOI":"10.1136\/bcr-2013-200552","volume":"2013","author":"D Dragnev","year":"2013","unstructured":"Dragnev D, Barr D, Kulshrestha M, et al. Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab. BMJ Case Rep. 2013;2013:bcr2013200552.","journal-title":"BMJ Case Rep"},{"key":"1948_CR65","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00415-012-6726-9","volume":"260","author":"Y Mao-Draayer","year":"2013","unstructured":"Mao-Draayer Y, Cash T. Neurosarcoidosis in a patient treated with tumor necrosis factor alpha inhibitors. J Neurol. 2013;260:651\u20133.","journal-title":"J Neurol"},{"key":"1948_CR66","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1600-0560.2011.01795.x","volume":"39","author":"AM Burns","year":"2012","unstructured":"Burns AM, Green PJ, Pasternak S. Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab. J Cutan Pathol. 2012;39:289\u201393.","journal-title":"J Cutan Pathol"},{"key":"1948_CR67","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.revmed.2011.03.336","volume":"33","author":"A Olivier","year":"2012","unstructured":"Olivier A, Gilson B, Lafontaine S, et al. Pulmonary and renal involvement in a TNF\u03b1 antagonist drug-induced sarcoidosis. Rev Med Interne. 2012;33:e25\u20137.","journal-title":"Rev Med Interne"},{"key":"1948_CR68","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.3899\/jrheum.080383","volume":"35","author":"VM Ognenovski","year":"2008","unstructured":"Ognenovski VM, Ojo TC, Fox DA. Etanercept-associated pulmonary granulomatous inflammation in patients with rheumatoid arthritis. J Rheumatol. 2008;35:2279\u201382.","journal-title":"J Rheumatol"},{"key":"1948_CR69","first-page":"1222","volume":"35","author":"AE Dubosc","year":"2008","unstructured":"Dubosc AE, Perroud A-M, Bagot M, et al. Cutaneous granulomas during infliximab therapy for spondyloarthropathy. J Rheumatol. 2008;35:1222\u20133.","journal-title":"J Rheumatol"},{"key":"1948_CR70","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/art.21336","volume":"53","author":"K Phillips","year":"2005","unstructured":"Phillips K, Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum. 2005;53:618\u201320.","journal-title":"Arthritis Rheum"},{"key":"1948_CR71","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1111\/1346-8138.14893","volume":"46","author":"T Ando","year":"2019","unstructured":"Ando T, Kamiya K, Maekawa T, et al. Adalimumab as a successful alternative for the treatment of infliximab-induced sarcoidosis. J Dermatol. 2019;46:e360-362.","journal-title":"J Dermatol"},{"key":"1948_CR72","doi-asserted-by":"publisher","first-page":"bcr2014208188","DOI":"10.1136\/bcr-2014-208188","volume":"2015","author":"I Berrios","year":"2015","unstructured":"Berrios I, Jun-Oonnell A, Ghiran S, Ionete C, et al. A case of neurosarcoidosis secondary to treatment of etanercept and review of the literature. BMJ Case Rep. 2015;2015:bcr2014208188.","journal-title":"BMJ Case Rep"},{"key":"1948_CR73","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s00393-016-0262-4","volume":"76","author":"JH Jung","year":"2017","unstructured":"Jung JH, Kim J-H, Song GG. Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept. Z Rheumatol. 2017;76:372\u20134.","journal-title":"Z Rheumatol"},{"key":"1948_CR74","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jbspin.2012.05.001","volume":"80","author":"C Vigne","year":"2013","unstructured":"Vigne C, Tebib J-G, Pacheco Y, et al. Sarcoidosis: an underestimated and potentially severe side effect of anti-TNF-alpha therapy. Joint Bone Spine. 2013;80:104\u20137.","journal-title":"Joint Bone Spine"},{"key":"1948_CR75","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nrgastro.2012.125","volume":"9","author":"I Cleynen","year":"2012","unstructured":"Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9:496\u2013503.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1948_CR76","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.4161\/mabs.32221","volume":"6","author":"SK Jung","year":"2014","unstructured":"Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima. MAbs. 2014;6:1163\u201377.","journal-title":"MAbs"},{"key":"1948_CR77","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ccm.2008.03.004","volume":"29","author":"E Bargagli","year":"2008","unstructured":"Bargagli E, Mazzi A, Rottoli P. Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum, and exhaled gas. Clin Chest Med. 2008;29:445\u201358.","journal-title":"Clin Chest Med"},{"key":"1948_CR78","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI114844","volume":"86","author":"B Rigat","year":"1990","unstructured":"Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion\/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343\u20136.","journal-title":"J Clin Invest"},{"key":"1948_CR79","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1183\/09031936.00050106","volume":"28","author":"H Biller","year":"2006","unstructured":"Biller H, Zissel G, Ruprecht B, et al. Genotype-corrected reference values for serum angiotensin-converting enzyme. Eur Respir J. 2006;28:1085\u201390.","journal-title":"Eur Respir J"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01948-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-01948-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01948-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T01:41:17Z","timestamp":1699666877000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01948-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1948"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01948-6","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"6 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a case report, and we did not receive any approval from the ethics review board. We obtained the patient's written informed consent to publish the material.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Fujiya reports grants and personal fees from Nippon Kayaku Co., Ltd., and Mitsubishi Tanabe Pharma Corporation as well as grants from AYUMI Pharmaceutical Corporation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"373"}}